GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (MEX:CRSP) » Definitions » Return-on-Tangible-Asset

CRISPR Therapeutics AG (MEX:CRSP) Return-on-Tangible-Asset : -15.51% (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is CRISPR Therapeutics AG Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. CRISPR Therapeutics AG's annualized Net Income for the quarter that ended in Sep. 2024 was MXN-6,769 Mil. CRISPR Therapeutics AG's average total tangible assets for the quarter that ended in Sep. 2024 was MXN43,645 Mil. Therefore, CRISPR Therapeutics AG's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2024 was -15.51%.

The historical rank and industry rank for CRISPR Therapeutics AG's Return-on-Tangible-Asset or its related term are showing as below:

MEX:CRSP' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -667.98   Med: -23.16   Max: 16.49
Current: -10.55

During the past 10 years, CRISPR Therapeutics AG's highest Return-on-Tangible-Asset was 16.49%. The lowest was -667.98%. And the median was -23.16%.

MEX:CRSP's Return-on-Tangible-Asset is ranked better than
73.92% of 1503 companies
in the Biotechnology industry
Industry Median: -39.43 vs MEX:CRSP: -10.55

CRISPR Therapeutics AG Return-on-Tangible-Asset Historical Data

The historical data trend for CRISPR Therapeutics AG's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG Return-on-Tangible-Asset Chart

CRISPR Therapeutics AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.49 -24.58 16.70 -25.31 -6.39

CRISPR Therapeutics AG Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.12 16.35 -19.76 -22.23 -15.51

Competitive Comparison of CRISPR Therapeutics AG's Return-on-Tangible-Asset

For the Biotechnology subindustry, CRISPR Therapeutics AG's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CRISPR Therapeutics AG's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where CRISPR Therapeutics AG's Return-on-Tangible-Asset falls into.



CRISPR Therapeutics AG Return-on-Tangible-Asset Calculation

CRISPR Therapeutics AG's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-2607.414/( (43729.255+37845.019)/ 2 )
=-2607.414/40787.137
=-6.39 %

CRISPR Therapeutics AG's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=-6768.896/( (42866.348+44423.877)/ 2 )
=-6768.896/43645.1125
=-15.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2024) net income data.


CRISPR Therapeutics AG  (MEX:CRSP) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


CRISPR Therapeutics AG Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


CRISPR Therapeutics AG Business Description

Traded in Other Exchanges
Address
Baarerstrasse 14, Zug, CHE, CH-6300
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.